Answers are grounded in this paper and cite their sources.
Urothelial carcinoma (UC) remains a diagnostic challenge due to the suboptimal sensitivity of current noninvasive tests and the invasive nature of reference standard procedures. Urine-based liquid biopsies targeting epigenetic and genetic alterations hold promise, but head-to-head comparisons across the full UC spectrum are lacking. This study aimed to systematically evaluate the diagnostic accuracy of cytology, fluorescence in situ hybridization (FISH), DNA methylation, and a 17‑gene mutation panel, both alone and in combination, to inform a practical, noninvasive diagnostic pathway. This prospective, single‑center cohort study enrolled 113 patients with hematuria and imaging‑suspected lesions (92 UC, including 60 upper tract urothelial carcinoma [UTUC] patients and 32 bladder cancer patients; 21 negative controls). Preoperative urine samples were tested using cytology, FISH, DNA methylation, and a 17‑gene mutation panel. The combined molecular assay was defined as positive if either DNA methylation or the 17-gene panel was positive (parallel OR rule). Diagnostic performance was assessed using the area under the curve (AUC), sensitivity, and specificity, with paired comparisons using the DeLong test. The combination of DNA methylation and the 17‑gene panel achieved the highest diagnostic accuracy (AUC = 0.865, sensitivity = 82.6%, specificity = 90.5%), outperforming cytology (AUC = 0.668), FISH (AUC = 0.652), and their combination (AUC = 0.723; all P < 0.05). In the UTUC subset, the incremental benefit of adding the 17-gene panel to DNA methylation was not statistically significant, and some paired comparisons with conventional tests were also non-significant, whereas molecular assays showed higher AUCs than conventional tests across all analysis sets. In symptomatic patients with hematuria and imaging-suspected lesions, a urine-based combination of DNA methylation and a 17-gene mutation panel offers high diagnostic accuracy and strong rule-in potential. These findings support its use as a noninvasive adjunct for triage and risk stratification in this high-prevalence population, but not for general population screening. Validation in larger, multicenter, low-prevalence cohorts is required before broader clinical application. ClinicalTrials.gov, NCT07614594.
No takes yet. Share an insight, caveat, or question.
Kunpeng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: